Taken together, these data indicate that reduction of BIM protein levels can desensitize ovarian cancer cells to the PI3K/mTOR and BCL-2/BCL-XL drug combination and further highlight the critical role of BIM levels in predicting drug sensitivity. The gene discussed is BCL2L1; the disease is ovarian carcinoma.